Latest news with #LLS
Yahoo
21-07-2025
- Health
- Yahoo
Poisoning prompts urgent plea to Aussies over invasive backyard plant
A poisoning has prompted a plea to Aussies to be aware of the grim truth lurking behind the alluring appearance of a 'pretty' plant often found on roadsides. While it might look like a harmless succulent, mother-of-millions — an invasive weed that escaped from suburban backyards — poses a serious risk to humans, pets, wildlife and livestock. The plant, native to Madagascar, is known for its striking red flowers that emerge every winter, however the blooms have a less than attractive side. The flowers are 'extremely toxic' to cattle, which 'often seek out alternative food sources when seasonal conditions impact pastures', a spokesperson for NSW's Local Land Services (LLS) told Yahoo News. A case of mother-of-millions poisoning in livestock was recently identified by a LLS veterinarian near Gravesend in the state's north west, the spokesperson explained, prompting a warning from the government agency. 'Cattle are the usual victims of poisonings,' the organisation posted online, adding ingesting even a small amount can cause diarrhoea, drooling, loss in appetite and death from heart failure. Livestock poisonings occur more frequently during the cooler months when 'plants are flowering, and frosts and dry weather have reduced palatable feed'. Popular backyard plant causes sudden death in livestock Mother-of-millions is also toxic to pets — especially dogs — and humans, but it's unlikely either would eat enough to become poisoned, according to NSW WeedWise. 'While mother-of-millions poisoning is uncommon, it can cause sudden death in livestock,' the LLS spokesperson told Yahoo. 'Livestock can die quite rapidly depending on the amount ingested and they can continue to die for a number of days after removal from the source. 'Landholders are encouraged to regularly inspect their properties and learn how to identify weeds such as mother-of-millions using NSW WeedWise, and report any new weed incursions to the Local Control Authority.' Invasive mother-of-millions can 'spread rapidly' Mother-of-millions, which was historically planted in gardens due to its ornamental qualities, is a declared weed in Queensland, but it's also considered a problem species in NSW and the Northern Territory, Imogen Ebsworth, the Invasive Species Council's (ISC) engagement director, told Yahoo. 'It spreads rapidly and can quickly take over natural areas if it escapes gardens,' she said. 'Because it's still legally sold and traded in many places, it's slipping under the radar — most Australians don't think of succulents as weeds.' However, experts are taking the plant very seriously. 'It was nominated as a Weed of National Significance, which is reserved for species with the potential to cause major environmental and economic damage,' Ebsworth explained. Following an assessment process, the species was not included. Mother-of-millions remains a weed of potential national significance and is widely distributed in the country's east. It can also be found in Victoria and parts of southern and Western Australia. The plant is frequently introduced to new areas in dumped garden waste and spreads in waterways or flood events. It is commonly found growing on sandy soils and disturbed sites such as roadsides, fence lines, and rubbish tips 🌱 Council's warning as popular plant sprouts up in 'hectic' location Aussies urged to dig up invasive plant that becomes 'very difficult to remove' 🏙️ Aussies told to check their backyards as popular plant 'infests' major city Calls to remove toxic weed from nurseries Ebsworth told Yahoo the ISC would 'love to see mother-of-millions removed from sale across the country'. 'Escaped garden plants are the primary source of new weeds in Australia,' she said, noting three-quarters of all listed weeds started out as ornamentals. She described the status quo as "a regulatory failure". "To date, self-regulation has failed. We are relying on everyday Australians to either have a botany degree or realise they need to research legally sold plants to find out if they are a weed. That's a system designed to fail.' In the meantime, Aussies are encouraged 'to be really careful' and refrain from tossing garden cuttings. 'Don't share or swap it, and if you need to dispose of it, bag it up securely and put it in the bin, not the compost,' Ebsworth you have a story tip? Email: newsroomau@ You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.
Yahoo
19-07-2025
- Health
- Yahoo
Plea to Aussies after 'pretty' roadside find leads to poisoning
A poisoning has prompted a plea to Aussies to be aware of the grim truth lurking behind the alluring appearance of a 'pretty' plant often found on roadsides. While it might look like a harmless succulent, mother-of-millions — an invasive weed that escaped from suburban gardens — poses a serious risk to humans, pets, wildlife and livestock. The plant, native to Madagascar, is known for its striking red flowers that emerge every winter, however the blooms have a less than attractive side. The flowers are 'extremely toxic' to cattle, which 'often seek out alternative food sources when seasonal conditions impact pastures', a spokesperson for NSW's Local Land Services (LLS) told Yahoo News. A case of mother-of-millions poisoning in livestock was recently identified by a LLS veterinarian near Gravesend in the state's north west, the spokesperson explained, prompting a warning from the government agency. 'Cattle are the usual victims of poisonings,' the organisation posted online, adding ingesting even a small amount can cause diarrhoea, drooling, loss in appetite and death from heart failure. Livestock poisonings occur more frequently during the cooler months when 'plants are flowering, and frosts and dry weather have reduced palatable feed'. Invasive plant causes sudden death in livestock Mother-of-millions is also toxic to pets — especially dogs — and humans, although incidents of poisoning in the latter are unlikely. 'While mother-of-millions poisoning is uncommon, it can cause sudden death in livestock,' the LLS spokesperson told Yahoo. 'Livestock can die quite rapidly depending on the amount ingested and they can continue to die for a number of days after removal from the source. 'Landholders are encouraged to regularly inspect their properties and learn how to identify weeds such as mother-of-millions using NSW WeedWise, and report any new weed incursions to the Local Control Authority.' Mother-of-millions can 'spread rapidly' if it escapes gardens Mother-of-millions, which was historically planted in gardens due to its ornamental qualities, is a declared weed in Queensland, but it's also considered a problem species in NSW and the Northern Territory, Imogen Ebsworth, the Invasive Species Council's (ISC) engagement director, told Yahoo. 'It spreads rapidly and can quickly take over natural areas if it escapes gardens,' she said. 'Because it's still legally sold and traded in many places, it's slipping under the radar — most Australians don't think of succulents as weeds.' However, experts are taking the plant very seriously. 'It was nominated as a Weed of National Significance, which is reserved for species with the potential to cause major environmental and economic damage,' Ebsworth explained. Following an assessment process, the species was not included. Mother-of-millions remains a weed of potential national significance and is widely distributed in the country's east. It can also be found in Victoria and parts of southern and Western Australia. It is introduced to new areas in dumped garden waste and spreads in waterways or flood events. 🌱 Council's warning as popular plant sprouts up in 'hectic' location Aussies urged to dig up invasive plant that becomes 'very difficult to remove' 🏙️ Aussies told to check their backyards as popular plant 'infests' major city Calls to remove toxic weed from Bunnings, nurseries Ebsworth told Yahoo the ISC would 'love to see mother-of-millions removed from sale across the country'. 'Escaped garden plants are the primary source of new weeds in Australia,' she said, noting three-quarters of all listed weeds started out as ornamentals. 'That's not a Bunnings problem or a rogue nursery problem — it's a regulatory failure. To date, self-regulation has failed. We are relying on everyday Australians to either have a botany degree or realise they need to research legally sold plants to find out if they are a weed. That's a system designed to fail.' In the meantime, Aussies are encouraged 'to be really careful' and refrain from tossing garden cuttings. 'Don't share or swap it, and if you need to dispose of it, bag it up securely and put it in the bin, not the compost,' Ebsworth said. Do you have a story tip? Email: newsroomau@ You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.
Malaysian Reserve
02-07-2025
- Health
- Malaysian Reserve
Cyclists of All Ages and Abilities to Unite for Blood Cancer Patients Along Picturesque Lake Michigan Shoreline
The Leukemia & Lymphoma Society's Scenic Shore Bike Tour Offers a Unique Ride Experience to Help Advance Lifesaving Research, Support, and Advocacy WASHINGTON, July 2, 2025 /PRNewswire/ — From July 26-27, over a thousand cyclists will converge in Mequon, Wisconsin, to participate in the 33rd Annual Scenic Shore Bike Tour. This fully supported, two-day cycling event spans 150 miles along the breathtaking Lake Michigan shoreline, uniting riders from across the nation to help blood cancer patients live longer better lives. Funds raised will drive forward The Leukemia & Lymphoma Society's (LLS) mission: cure blood cancers and improve the lives of patients and their families. For more than 75 years, LLS has led the fight against blood cancers, achieving groundbreaking progress in research, patient support, and advocacy. 'Scenic Shore is more than a bike ride; it's a powerful movement where riders of all skill levels pedal together to support blood cancer patients,' said Coker Powell, LLS Executive Vice President and Chief Revenue Officer. 'Whether you're riding solo, with family, or as part of a team, your efforts bring hope and make an incredible difference.' From road bikes to e-bikes, cyclists including cancer survivors and supporters will ride to help LLS's bold goal for the future: to enable blood cancer patients to gain more than one million years of life by 2040. Participants can select routes that suit their abilities, including 25-mile, 75-mile, or the classic 150-mile, two-day experience. This year's ride holds special significance for LLS's Chief Medical Officer, Gwen Nichols, M.D. and her son, Jesse Rost (who graduated from the University of Wisconsin-Madison ten years ago), as they return to the region to pedal on behalf of blood cancer patients and families. 'At this time in history, when research cuts threaten progress for patients and the cost of care continues to rise, donations are more important than ever,' said Dr. Nichols. 'Everything we do at LLS is patient-focused—from advancing lifesaving blood cancer treatments, to providing individualized support, to fighting for policies that help families access the care and resources they need and deserve. I'm so honored to be pedaling alongside my son and LLS staff and supporters as we raise critical funds for our mission.' Two special blood cancer survivors/advocates who became friends through their participation in Scenic Shore will be in attendance for the event: Jessica Salmonowicz, this year's Scenic Shore Honored Hero, and Paul Westrick. Salmonowicz, a leukemia survivor, whose life was saved by LLS-funded research, joined Scenic Shore in 2012 and continues to ride in gratitude. Westrick joined in 2008, while in remission from multiple myeloma. He credits LLS research for extending his life and aims to return after he recovers from his second stem cell transplant. United by their shared experiences, Salmonowicz and Westrick are inspiring others to support LLS's lifesaving mission and thrive as part of the blood cancer community. It's not too late to make an impact! Register now to join the ride of a lifetime here. Event Details Saturday, July 26, 2025 Start Location: Concordia University, Mequon, WI Distance Options: 25, 75, or 100 miles Highlights: 7:30 AM kickoff with an energizing opening ceremony Riders traverse 75 miles to the University of Wisconsin-Green Bay at Manitowoc Evening festivities featuring refreshments, dinner, live music, and awards lakeside 7:30 AM kickoff with an energizing opening ceremony Riders traverse 75 miles to the University of Wisconsin-Green Bay at Manitowoc Evening festivities featuring refreshments, dinner, live music, and awards lakeside Sunday, July 27, 2025 End Location: John Miles Park, Sturgeon Bay, WI Distance: 75 miles Highlights: Morning hot breakfast before the final leg Riders arrive in Door County for a celebratory Tailgate Festival Deluxe coach buses transport riders back to the starting location Morning hot breakfast before the final leg Riders arrive in Door County for a celebratory Tailgate Festival Deluxe coach buses transport riders back to the starting location About The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society® (LLS) is the global leader and innovator in creating a world without blood cancer. The LLS mission: Cure blood cancer and improve the quality of life of all patients and their families. LLS is focused on accelerating research, providing free support and services, and advocating for policies to ensure access to quality, affordable care. For more than 75 years, LLS has been helping blood cancer patients live longer, better lives. To learn more, visit Patients can contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET. Connect with us on Facebook, X, Instagram, LinkedIn and TikTok. LLS Media Contact: mediarelations@
Yahoo
12-06-2025
- Business
- Yahoo
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL) $9 million from new investor The Institute for Follicular Lymphoma Innovation (IFLI) $10 million from existing specialist investors, including The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Paris, France – June 12, 2025Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial. New U.S. investor The Institute for Follicular Lymphoma Innovation (IFLI), a global non-profit foundation dedicated to advancing research and treatment for follicular lymphoma, invested $9 million in the round, of which $5 million will be allocated to Enterome upon closing and an additional $4 million in conditional tranched funding. Existing shareholders invested an additional $10 million including: SymBiosis, a U.S. venture capital firm; Seventure Partners, based in France; Lundbeckfonden BioCapital from Denmark; Primo Capital, an Italian venture capital and private equity firm; and The U.S. Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP). 'Attracting highly specialized blood cancer investor IFLI to this financing demonstrates the conviction of our new and existing investors in the potential of OncoMimics™ for blood and solid tumor cancers,' said Pierre Bélichard, Enterome's Chief Executive Officer. 'We currently are generating exciting clinical proof of concept data for EO2463 monotherapy in several iNHL patient populations included in the Phase 1/2 SIDNEY clinical trial. Most importantly, EO2463 has shown robust clinical efficacy and exceptional safety and tolerability – which is especially impressive for such a potent immunotherapy. This offers a new hope for these patients and a rare opportunity to create an entirely new market segment for an impactful therapeutic. This financing will enable us to continue the SIDNEY trial of EO2463 and prepare to launch a first pivotal Phase 3 trial of this candidate for the 'watch-and-wait' iNHL population.' The company presented interim SIDNEY dataat the American Society of Hematology (ASH) conference in December 2024, showing highly encouraging responses in the Cohort 2 of 'watch and wait' iNHL patients in the ongoing SIDNEY study. This population, as the name suggests, is generally not eligible to receive other treatments due to the unacceptable risk-benefit ratio (in this iNHL sub-population) of the most commonly used blood cancer therapies. The company also recently disclosed having held positive meetings with both FDA (Type C meeting) and EMA (Scientific Advice), outlining a clear regulatory path registration for marketing authorizations in 'watch-and-wait' iNHL. 'This investment aligns with IFLI's mission to accelerate the development of innovative therapies and precision biomarkers for follicular lymphoma,' said Michel Azoulay, MD, Chief Medical Officer at IFLI. 'EO2463 represents a novel class of synthetic, off-the-shelf Immunotherapeutics with a unique mechanism of action that selectively targets malignant B cells. We are particularly interested in supporting Enterome's efforts to demonstrate EO2463's clinical efficacy across multiple lines of therapy, including in relapsed and refractory settings.' Enterome recently announced that it will present new data showing EO2463 also has a meaningful impact when tested in combination with standard of care in relapsed and refractory iNHL patients at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21. Previous findings presented at ASCO in 2024 in the relapsed and refractory patient population further suggested the potential to identify individuals most likely to benefit from EO2463 treatment, supported by biomarker analyses. Lore Gruenbaum, Chief Scientific Officer at LLS, said, 'It is important for us to continue to support Enterome, a company working to develop novel therapeutics based on our shared commitment to create better therapies for blood cancers. LLS has invested over $1.8 billion in groundbreaking research since our inception in 1949. Our active partnership with Enterome, through our Therapy Acceleration Program, will continue to advance the clinical development of the OncoMimics™ family of novel immunotherapeutics for the benefit of blood cancer patients. We are particularly excited to help advance EO2463 which has shown promising signs of efficacy as monotherapy with excellent safety and tolerability in 'watch-and-wait' iNHL patients, who currently have no approved treatment options.' EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimics™ peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that mimic the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). EO2463 also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes. By ensuring broad target coverage across malignant B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells' capacity to develop immune-resistance mechanisms such as antigen escape. SIDNEY is an ongoing 12-month open label Phase 1/2 study that aims to assess safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in up to about 55 patients with follicular lymphoma and marginal zone lymphoma including divided into three cohorts: newly diagnosed patients eligible to watch-and-wait (monotherapy); newly diagnosed patients in need of therapy / first line (combo with rituximab); patients with relapsed/refractory disease (combo with R2). In addition to safety, survival, response rates and other measures of efficacy are being collected. OncoMimics™ were inspired by the microbial origin of certain autoimmune diseases. The Company uses AI and machine learning to identify microbial proteins that closely mimic the structure, effect or actions of specific cancer antigens (as well as hormones or cytokines). Memory T cells against microbial antigen are created during early development, sometimes leading to autoimmune disorders. In the case of OncoMimics™, however, this means that the immune system can mount a rapid, robust and durable immune response that is highly targeted and specific for the OncoMimics™ and the cancer antigens they closely resemble. This is possible because, unlike cancer antigens, OncoMimics™ bypass the biological process, known as thymic deletion, that prevents the immune system from mounting an attack against the 'self' proteins (e.g. antigen) on tumor and blood cancer cells. Once activated, the immune system attacks with high specificity and potency the cancer antigens targeted by the OncoMimics™, killing the cancer cells that carry them. OncoMimics™ are synthetic peptides that are easy to manufacture, store, distribute and administer as an off-the-shelf subcutaneous injection. In clinical testing to date they have been shown to be extremely well tolerated, especially compared to other potent immunotherapies. Enterome SA ( is a privately held clinical-stage biopharmaceutical company developing OncoMimics™, a new proprietary immunotherapeutic modality inspired by the microbial origin of certain autoimmune diseases, to treat cancer. The Company's wholly-owned OncoMimics™ pipeline includes three distinct clinical-stage drug candidates: EO2463 to treat indolent non-Hodgkin lymphomas; EO4010 to treat third-line colorectal cancer; and EO2401 to treat glioblastoma and adrenal tumors. Each of these candidates has shown positive early clinical efficacy and exceptional safety and tolerability. For more information, please contact: ENTEROME INVESTOR & MEDIA RELATIONS Pierre BélichardChief Executive Officer +33 (0)1 75 77 27 85 Cohesion BureauChris Maggos / Giovanni Ca' Zorzi +41 (0)79 367 6254 / +33 (0)7 84 67 07 27enterome@ Attachment 20250612_Enterome _PR_Funding_Round_finalError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-06-2025
- Business
- Yahoo
Subaru Celebrates Ten Years Partnering With the Leukemia & Lymphoma Society To Support Nearly 500,000 Cancer Patients and Families Nationwide
CAMDEN, NJ / / June 2, 2025 / Automaker provides relief and support through funding, physical donations, and messages of hope Subaru of America, Inc. today announced a major milestone, marking the tenth consecutive year of partnering with The Leukemia & Lymphoma Society® (LLS) as part of its Subaru Loves to Care® initiative. As the largest automotive donor to LLS, Subaru and its retailers are committed to supporting children and families affected by blood cancer, and by the end of 2025, will have helped nearly 500,000 cancer patients nationwide. The treatment and recovery for blood cancer patients can be long, difficult, and emotionally draining, often leaving individuals feeling isolated and physically weakened. In response, Subaru and its retailers bring warmth and compassion through the delivery of custom heart-shaped blankets, curated care kits, and handwritten messages of hope. These gestures provide valuable relief and reinforce the importance of community support. Alan Bethke, Senior Vice President of Marketing at Subaru of America, Inc.: "A decade of working together on Subaru Loves to Care has only served to reinforce how meaningful a personal touch can be for those facing cancer. Hand in hand with our retailers and The Leukemia & Lymphoma Society, we remain committed to delivering warmth, love, and comfort during some of life's most difficult moments. This partnership helps make a difference by reminding cancer patients how many people are rooting for them." Throughout June, over 630 participating retailers across the country will continue sharing hope by delivering blankets and personal messages to cancer patients in local hospitals. Additionally, 370 of those participating retailers will provide care kits to offer added comfort throughout treatment and recovery. Through these continued efforts, Subaru strengthens its promise to be More Than a Car Company®, one blanket and note at a time. In addition to donating and delivering blankets, messages of hope, and care kits, participating retailers are also contributing to The Leukemia & Lymphoma Society's Urgent Need Pediatric, Adolescent and Young Adult Fund. The fund provides financial assistance to young blood cancer patients and their families to help with non-medical related expenses, from groceries to transportation, housing and more. Along with these contributions from retailers, Subaru will match donations made through during Subaru Loves to Care between June 1 and 30, 2025, up to $100,000 in total. E. Anders Kolb, M.D., President and CEO of The Leukemia & Lymphoma Society: "Thoughtful gestures like blankets and handwritten notes from Subaru and its retailers offer real comfort, love, and encouragement during treatment, especially for children. When I think about the number of lives we have touched over the past ten years, it fills my heart to know that so many patients were reminded that they're not alone. That simple act of kindness is one that leaves a lasting effect." Those looking to write messages of hope for patients in their community are invited to visit their local Subaru retailer. For more information on Subaru Loves to Care, visit and follow #SubaruLovestoCare on social media to see this initiative in action. To learn more about the Subaru Love Promise, visit ### About Subaru of America, of America, Inc. (SOA) is an indirect wholly owned subsidiary of Subaru Corporation of Japan. Headquartered in Camden, N.J., the company markets and distributes Subaru vehicles, parts, and accessories through a network of about 640 retailers across the United States. All Subaru products are manufactured in zero-landfill plants, including Subaru of Indiana Automotive, Inc., the only U.S. automobile manufacturing plant designated a backyard wildlife habitat by the National Wildlife Federation. SOA is guided by the Subaru Love Promise, which is the company's vision to show love and respect to everyone and to support its communities and customers nationwide. Over the past 20 years, SOA and the SOA Foundation have donated more than $320 million to causes the Subaru family cares about, and its employees have logged over 100,000 volunteer hours. Subaru is dedicated to being More Than a Car Company® and to making the world a better place. For additional information, visit Follow us on Facebook, Instagram, LinkedIn, TikTok, and YouTube. About The Leukemia & Lymphoma SocietyThe Leukemia & Lymphoma Society® (LLS) is the global leader and innovator in creating a world without blood cancer. The LLS mission: Cure blood cancer and improve the quality of life of all patients and their families. LLS is focused on accelerating research, providing free support and services, and advocating for policies to ensure access to quality, affordable care. For more than 75 years, LLS has been helping blood cancer patients live longer, better lives. To learn more, visit Patients can contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET. Connect with us on Facebook, X, Instagram, LinkedIn and TikTok. Media Contacts Diane AntonCorporate Communications Manager(856) 488-5093danton@ Adam LeiterCorporate Communications Specialist(856) 488-8668aleiter@ Subaru of America, Inc. partners with The Leukemia & Lymphoma Society® (LLS) for the tenth consecutive year as part of the Subaru Loves to Care® initiative. Subaru is the largest automotive donor to LLS, and by the end of 2025, Subaru and its retailers will have supported nearly 500,000 cancer patients around the country with funding, blanket donations, and messages of hope through this continued partnership. View additional multimedia and more ESG storytelling from Subaru of America on Contact Info:Spokesperson: Subaru of AmericaWebsite: Email: info@ SOURCE: Subaru of America View the original press release on ACCESS Newswire Sign in to access your portfolio
